AstraZeneca inks up to $1.77B CSPC deal for experimental kidney drugs
AZN•AZN•AZN•AZN•AstraZeneca has agreed a collaboration with CSPC Pharmaceutical Group valued at up to $1.77 billion to discover and develop experimental kidney disease drugs in China. The deal grants CSPC funding responsibility and milestone-based payments spanning research, development and commercial stages, expanding AstraZeneca's nephrology pipeline and China footprint.
AstraZeneca and CSPC Pharmaceutical Group have formed a collaboration worth up to $1.77 billion to co-discover and develop experimental kidney disease therapies in China. The agreement leverages AstraZeneca’s research capabilities with CSPC’s local development and commercialization network.
Under the terms, CSPC will fund discovery and development activities, triggering milestone payments through clinical stages and potential commercial launch. The collaboration enhances AstraZeneca’s nephrology pipeline while strengthening its strategic presence in the Chinese pharmaceutical market.
